WAT Waters Corporation
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Waters (NYSE: WAT)
›
Waters (NYSE: WAT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 15,000 employees.
The shares were at 456.48 USD on 19 November 2026, up 20.3% over 52 weeks. Its 52-week range is 282.77 USD to 483.33 USD: the price is 5.6% below the high and 61.4% above the low.
At a market capitalisation of 89.71B USD, it trades at 191.0 times trailing earnings and 27.6 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 447% for WAT.
Waters reports return on equity of 25.1%, an operating margin of 16.0% and revenue up 120.9% year over year.
Its debt exceeds its cash by 4.92B USD, a debt-to-equity ratio of 0.58. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 503.29 USD is 10.3% above the current price. The next earnings report is expected on 10 February 2027.